Folate receptor alpha expression in lung cancer: Diagnostic and prognostic significance

Oncotarget

Volumn 3, Issue 4, 2012, Pages 414-425

  O'Shannessy, Daniel J ^a   Yu, Gordon ^b   Smale, Robert ^c   Fu, Yao Shi ^c   Singhal, Sunil ^b   Thiel, Robert P ^d   Somers, Elizabeth B ^a   Vachani, Anil ^b  

^a Morphotek Inc   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LABORATORY CORPORATION OF AMERICA   (United States)

^d THIEL Statistical Consultants   (United States)

Author keywords

Adenocarcinoma; Folate receptor alpha; FRA; Immunohistochemistry; Non small cell lung cancer; Prognosis

Indexed keywords

FOLATE RECEPTOR 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 26B3; PARAFFIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MOLECULAR PATHOLOGY; NEEDLE BIOPSY; OVERALL SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; TISSUE MICROARRAY; AGED; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; PROTEIN MICROARRAY; SURVIVAL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLATE RECEPTOR 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN ARRAY ANALYSIS; SURVIVAL ANALYSIS;

EID: 84864259555     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.519     Document Type: Article

References (36)

1. Elnakat H and Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004; 56(8):1067-1084.
2. Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, Kamen BA, Low PS and Knutson KL. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One. 2009; 4(7):e6292.
3. Reddy JA, Haneline LS, Srour EF, Antony AC, Clapp DW and Low PS. Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood. 1999; 93(11):3940-3948.
4. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS and Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005; 338(2):284-293.
5. Toffoli G, Russo A, Gallo A, Cernigoi C, Miotti S, Sorio R, Tumolo S and Boiocchi M. Expression of folate binding protein as a prognostic factor for response to platinumcontaining chemotherapy and survival in human ovarian cancer. Int J Cancer. 1998; 79(2):121-126.
6. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M and Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997; 74(2):193-198.
7. Iwakiri S, Sonobe M, Nagai S, Hirata T, Wada H and Miyahara R. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol. 2008; 15(3):889-899.
8. Li W, Tan G, Ma Y, Li H and He G. Inhibition of alpha Folate Receptor Resulting in a Reversal of Taxol Resistance in Nasopharyngeal Carcinoma. Otolaryngol Head Neck Surg. 2011.
9. Antony AC. The biological chemistry of folate receptors. Blood. 1992; 79(11):2807-2820.
10. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS and Kamen BA. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res. 1992; 52(23):6708-6711.
11. Low PS and Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009; 13(3):256-262.
12. Dosio F, Milla P and Cattel L. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs. 2010; 11(12):1424-1433.
13. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM and Grasso L. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007; 7:6.
14. Spannuth WA, Sood AK and Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther. 2010; 10(3):431-437.
15. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM and Old LJ. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010; 16(21):5288-5295.
16. Shia J, Klimstra DS, Nitzkorski JR, Low PS, Gonen M, Landmann R, Weiser MR, Franklin WA, Prendergast FG, Murphy L, Tang LH, Temple L, Guillem JG, Wong WD and Paty PB. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol. 2008; 39(4):498-505.
17. Franklin WA, Waintrub M, Edwards D, Christensen K, Prendegrast P, Woods J, Bunn PA and Kolhouse JF. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl. 1994; 8:89-95.
18. Stein R, Goldenberg DM and Mattes MJ. Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest. Int J Cancer. 1991; 47(2):163-169.
19. O'Shannessy DJ, Somers EB, Albone E, Cheng X, Park YC, Tomkowicz BE, Hamuro Y, Kohl TO, Forsyth TM, Smale R, Fu YS and Nicolaides NC. Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget. 2011; 2(12):1227-1243.
20. Smith AE, Pinkney M, Piggott NH, Calvert H, Milton ID and Lunec J. A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues. Hybridoma (Larchmt). 2007; 26(5):281-288.
21. Clopper CJ and Pearson RC. The use of confidence or fiducial limits Illustrated in the case of the binomial. Biometrika. 1934; 26:404-413.
22. Pepe MS. (2003). The Statistical Evaluation of Medical Tests for Classification and Prediction. (New York: Oxford University Press).
23. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, Jr. and Kamen BA. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992; 52(12):3396-3401.
24. Selhub J, Emmanouel D, Stavropoulos T and Arnold R. Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. Am J Physiol. 1987; 252(4 Pt 2):F750-756.
25. Selhub J, Nakamura S and Carone FA. Renal folate absorption and the kidney folate binding protein. II. Microinfusion studies. Am J Physiol. 1987; 252(4 Pt 2):F757-760.
26. Elnakat H and Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci. 2006; 11:506-519.
27. Weitman S, Anderson RGW and Kamen BA. (1994). Folate binding proteins. In: Dakshinamurthi K, ed. Vitamin Receptors: Vitamins as Ligands in Cell Communication: Cambridge University Press), pp. 106-136.
28. Ghitis J. The labile folate of milk. Am J Clin Nutr. 1966; 18(6):452-457.
29. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27(8):1227-1234.
30. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH. Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-2550.
31. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-3551.
32. Field RW, Smith BJ, Platz CE, Robinson RA, Neuberger JS, Brus CP and Lynch CF. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004; 96(14):1105-1107.
33. Khayyata S, Yun S, Pasha T, Jian B, McGrath C, Yu G, Gupta P and Baloch Z. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 2009; 37(3):178-183.
34. Ou SH and Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol. 2009; 4(10):1202-1211.
35. Coate LE, John T, Tsao MS and Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol. 2009; 10(10):1001-1010.
36. Zhu CQ, Shih W, Ling CH and Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006; 59(8):790-800.